Skip navigation

Leadership Seminar: The Impact of Genomics on Drug Development

10:00 – 18:30

Location:
EMBL-EBI, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD
Date:
11 October 2016
 
In partnership with: 
   

Genomics, particularly high-throughput sequencing and characterisation of expressed human genes, has created extensive new opportunities for drug discovery. Knowledge of all the human genes and their functions not only sees applications in diagnostics but could also completely change drug research strategy and development processes.
 
This Leadership Seminar will review recent developments in genomics especially in sequencing technologies, data management and analysis and discuss how they are influencing the drug discovery and development landscape. 
It will lead to broader industry discussions on how the pharmaceutical companies are incorporating these technologies in terms of collaborations and resources.   
 
This event is aimed at anybody from academia or industry with an interest in genomics and its impact on the pharmaceutical industry. 
 
Programme:

10.00 - Registration and Coffee

10.30 - Welcome from the Hosts 

10.45 - Is Genomics the New Catalyser of Drug Development Partnerships?

10.45 - Open Innovation Partnerships to Bridge the Gap From GWAS to Drug Targets
Jeffrey Barrett, Director, Open Targets

Click here to view the presentation


11.05 - Genomics Solutions for Target Identification and Validation in Drug Development
Coralie Vacher, Illumina

Click here to view the presentation


11.25 - Genomics in Drug Development
Mahdi Farhan, Roche

11.45 - Targeting Cancer Vulnerabilities  
Mathew Garnett, Sanger Institute 

Click here to view the presentation

12.15 - Lunch

13.20 - Keynote Address
Dennis Davin, Secretary of Economic Development of Pennsylvania

13.35 - Genomics Supporting Drug Discovery 

13.35 - Global Alliance for Genomics and Health
Stephen Keenan, EMBL-EBI

14.05 - Utilisation of CRISPR Genome Editing in Drug Development 
Leigh Brody
, Desktop Genetics

Click here to view the presentation

14.25 - Improving Access to Patient Derived Xenograft Data 
Manuel Corpas, Repositive 

14.45 - Mutation-Rich Cancer Genomes: Impact on Diagnostics and Prediction
Serena Nik-Zainal, Sanger Institute 

15.05 - Illuminating the Druggable Genome
Anna Gaulton
, EMBL-EBI
Click here to view the presentation

15.25 - Coffee Break

15.50 - Genomics supporting drug development 

15.50 - Standards and Services BRIDGing and SHARE-ing Regulated Pharmacogenomics Research
Lauren Becnel, CDISC 

16.10 - Community analysis to predict therapeutic synergy within the AstraZeneca-Sanger Drug Combination Challenge
Michael Menden, AstraZenca
Click here to view the presentation

16.30 - Centre for Genomic Pathogen Surveillance 
David Aanensen, Sanger Institute

16.50 - Closing remarks 
Stephen Minger

17.10 - Drinks and Networking

18.30 - Close
           

Prices:
Gold Members - £75 + VAT 
Silver Members - £175 + VAT 
Non-member - £275 + VAT

Academics - £75 + VAT 


Please email aline@onenucleus.com to get your academic discount code
 

To view the ON Insights written in relation to this event, please click here.
Title: Leadership Seminar: The Impact of Genomics on Drug Development
Start: 2016-10-11 10:00:00Z
End: 2016-10-11 18:30:00Z